BACKGROUND: The polymorphism of XRCC3 Thr241Met has been indicated to be correlated with glioma susceptibility, but study results are still debatable. The present meta-analysis was performed to investigate the association between XRCC3 Thr241Met polymorphism and glioma. METHODS: A total of 3754 glioma patients and 4849 controls from nine separate studies were involved. The pooled odds ratio (OR) and its corresponding 95% confidence interval (CI) was assessed by the random-effects model. RESULTS: The association between XRCC3 Thr241Met polymorphism and glioma was significant in the recessive model (OR = 1.36; 95% CI, 1.02 - 1.82; P = 0.03). In a stratified analysis by the ethnicity, significantly increased risk was detected in Asians (OR = 1.93; 95% CI, 1.18 - 3.17; P = 0.009). CONCLUSIONS: In conclusion, XRCC3 Thr241Met polymorphism was implied to be associated with increased glioma risk. More studies are needed to validate this result.
BACKGROUND: The polymorphism of XRCC3 Thr241Met has been indicated to be correlated with glioma susceptibility, but study results are still debatable. The present meta-analysis was performed to investigate the association between XRCC3 Thr241Met polymorphism and glioma. METHODS: A total of 3754 gliomapatients and 4849 controls from nine separate studies were involved. The pooled odds ratio (OR) and its corresponding 95% confidence interval (CI) was assessed by the random-effects model. RESULTS: The association between XRCC3 Thr241Met polymorphism and glioma was significant in the recessive model (OR = 1.36; 95% CI, 1.02 - 1.82; P = 0.03). In a stratified analysis by the ethnicity, significantly increased risk was detected in Asians (OR = 1.93; 95% CI, 1.18 - 3.17; P = 0.009). CONCLUSIONS: In conclusion, XRCC3 Thr241Met polymorphism was implied to be associated with increased glioma risk. More studies are needed to validate this result.
Authors: Yanhong Liu; Michael E Scheurer; Randa El-Zein; Yumei Cao; Kim-Anh Do; Mark Gilbert; Kenneth D Aldape; Qingyi Wei; Carol Etzel; Melissa L Bondy Journal: Cancer Epidemiol Biomarkers Prev Date: 2009-01 Impact factor: 4.254
Authors: Mathew Lozinski; Nikola A Bowden; Moira C Graves; Michael Fay; Paul A Tooney Journal: Cell Oncol (Dordr) Date: 2021-05-31 Impact factor: 6.730